膀胱癌组织miRNA-218、ACSS3表达及其与患者临床病理特征、预后的关系  

Expression of miRNA-218 and ACSS3 in bladder cancer tissues and their relationship with clinicopathological features and prognosis of patients

作　　者：杜凌云 王善龙 唐晓梅[2] DU Ling-yun;WANG Shan-long;TANG Xiao-mei(Department of Urology,Yulin Traditional Chinese Medicine Hospital,Yulin Shaanxi 719000,China;Department of Pathology,Baoji People's Hospital,Baoji Shaanxi 721000,China)

机构地区：[1]榆林市中医医院泌尿外科,陕西榆林719000 [2]宝鸡市人民医院病理科,陕西宝鸡721000

出　　处：《临床和实验医学杂志》2025年第3期264-269,共6页Journal of Clinical and Experimental Medicine

基　　金：陕西省自然科学基金资助项目(编号:2023-JC-YB 682)。

摘　　要：目的探讨膀胱癌组织微RNA(miRNA)-218、酰基辅酶A合成酶短链家族成员3(ACSS3)表达及其与患者临床病理特征、预后的关系。方法选取2020年5月至2023年5月于榆林市中医医院泌尿外科行手术治疗的108例膀胱癌患者作为研究对象,将患者的癌组织标本纳入膀胱癌组,对应癌旁组织标本纳入癌旁组。采用实时荧光定量聚合酶链式反应(qRT-PCR)检测miRNA-218,采用免疫组织化学法检测ACSS3,比较两组标本组织的miRNA-218表达水平以及ACSS3阳性率;比较不同临床病理特征膀胱癌患者癌组织miRNA-218表达水平、ACSS3阳性率。术后短期随访1年,观察记录膀胱癌患者预后生存情况,其中预后不良组36例、预后良好组72例。Logistic回归分析影响膀胱癌患者预后生存的因素,分析miRNA-218、ACSS3单独以及联合检测对膀胱癌患者预后的价值并绘制受试者工作特征(ROC)曲线;Kaplan-Meier法绘制生存曲线,比较不同miRNA-218表达水平、ACSS3阳性与阴性膀胱癌患者生存时间。结果膀胱癌患者癌组织中miRNA-218表达水平、ACSS3阳性率分别为2.64±0.41、24.07%,均低于癌旁组织(3.78±0.72、87.04%),差异均有统计学意义(P<0.05)。与TNM分期为Ⅰ~Ⅱ期、肿瘤病理分级低级、无淋巴结转移的膀胱癌患者相比,miRNA-218表达水平以及ACSS3阳性率在Ⅲ~Ⅳ期、肿瘤病理分级高级、有淋巴结转移的膀胱癌患者更低,差异均有统计学意义(P<0.05)。预后不良组TNM分期Ⅲ~Ⅳ期、肿瘤病理分级高级、有淋巴结转移患者占比高于预后良好组,ACSS3阳性表达患者占比、miRNA-218表达水平低于预后良好组,差异均有统计学意义(P<0.05)。TNM分期Ⅲ~Ⅳ期、肿瘤病理分级高级、有淋巴结转移、miRNA-218低表达、ACSS3阳性率低是膀胱癌患者预后不良的独立危险因素(P<0.05)。ROC曲线分析结果显示,miRNA-218、ACSS3联合检测预测膀胱癌患者预后的AUC值高于单项检测(P<0.05)。miRNA-218>Objective To investigate the expression of microRNA(miRNA)-218 and acyl-CoA synthetase short chain family member 3(ACSS3)in bladder cancer tissues and their relationship with clinicopathological features and prognosis of patients.Methods A total of 108 patients with bladder cancer who underwent surgical treatment in the Department of Urology,Yulin Traditional Chinese Medicine Hospital from May 2020 to May 2023 were selected as the research objects.The cancer tissue samples of the patients were included in the bladder cancer group,and the corresponding paracancerous tissue samples were included in the paracancerous group.Real-time fluorescence quantitative polymerase chain reaction(qRT-PCR)was used to detect miRNA-218,and immunohistochemistry was used to detect ACSS3.The expression level of miRNA-218 and the positive rate of ACSS3 were compared between the two groups.The expression level of miRNA-218 and the positive rate of ACSS3 in cancer tissues of bladder cancer patients with different clinicopathological features were compared.The patients were followed up for 1 year after operation,and the prognostic survival of bladder cancer patients was observed and recorded.There were 36 cases in the poor prognosis group and 72 cases in the good prognosis group.Logistics regression model was used to analyze the prognostic factors of bladder cancer patients.The predictive value of miRNA-218,ACSS3 alone and combined detection on the prognosis of bladder cancer patients was analyzed by drawning the receiver operating characteristic curve(ROC).The survival curve was drawn by Kaplan-Meier method,and the survival time of patients with different miRNA-218 expression levels,ACSS3 positive and negative bladder cancer was compared.Results The expression level of miRNA-218 and the positive rate of ACSS3 in bladder cancer tissues were 2.64±0.41 and 24.07%,respectively,which were lower than those in adjacent tissues(3.78±0.72 and 87.04%),and the differences were statistically significant(P<0.05).Compared with bladder cancer patient

关 键 词：膀胱肿瘤 微RNA-218 酰基辅酶A合成酶短链家族成员3 临床病理特征 预后 

分 类 号：R737.14[医药卫生—肿瘤]